| Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. | |
| | |
MedLine Citation:
|
PMID: 3995683 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ten human leukemia-lymphoma cell lines were tested for the growth-inhibitory effects of harringtonine (HT). HT was most active against HL-60 acute promyelocytic leukemia cells and least active against DND-41 acute lymphoblastic leukemia cells, with a 70-fold differential activity. Sensitivity of the cell lines is, in decreasing order: HL-60 greater than RPMI-8402 greater than DND-39A congruent to ML-2 congruent to MOLT-3 congruent to KG-1 greater than Daudi congruent to NALL-1 greater than BALM-2 greater than DND-41. The cell lines with rapid cell growth tended to be more sensitive to HT. To further elucidate the selectivity of the differential sensitivity, uptake and release of HT were compared in HL-60 and DND-41 cells. Uptake of [3H]HT into HL-60 and DND-41 cells showed no difference; however, the binding of [3H]HT to cellular components was greater than 16-fold higher in HL-60 cells than DND-41 cells. There were also minor, but significant differences in the inhibition of [3H]leucine incorporation into proteins of these two cell lines in the presence of 1 microgram/ml HT. To test whether the biological effects of HT are related to the concentration of, or exposure time to, HT, KG-1 cells were exposed to HT for different periods of time and the growth-inhibitory effects were compared. Increasing exposure time from 1 h to 3 h resulted in a 100-fold decrease in concentration X exposure time (c X t) at ID50; from 3 h to 6 h, in a 20-fold decrease at ID70; and from 6 h to 24 h, in a 16-fold decrease at ID90. HT was not inactivated by cells up to 24 h. These results indicate that (a) the sensitivity of different cell lines to HT may be related to the degree of HT binding; and (b) the effects of HT are more dependent on exposure time than concentration. Continuous infusion is thus rational for clinical trials of this drug, and the degree of HT binding to leukemic cells may be predictive of clinical response. |
| | |
Authors:
|
Y Takemura; T Ohnuma; T C Chou; T Okano; J F Holland |
Related Documents
:
|
20677183 - Toxicological aspects of long-term treatment of keratinocytes with zno and tio2 nanopar... 3686343 - Nerve growth factor (ngf) sensitizes human medullary thyroid carcinoma (hmtc) cells for... 19528453 - A novel iodomethylene-dimethyl-dihydropyranone induces g2/m arrest and apoptosis in hum... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 14 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 1985 |
Date Detail:
|
Created Date: 1985-06-27 Completed Date: 1985-06-27 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: GERMANY, WEST |
Other Details:
|
Languages: eng Pagination: 206-10 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alkaloids
/
pharmacology* Cell Line Dose-Response Relationship, Drug Harringtonines / metabolism, pharmacology* Humans Leucine / metabolism Leukemia / pathology* Lymphoma / pathology* Time Factors Tritium / diagnostic use |
| Grant Support | |
ID/Acronym/Agency:
|
CA-25865/CA/NCI NIH HHS; CA-27569/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Alkaloids; 0/Harringtonines; 10028-17-8/Tritium; 61-90-5/Leucine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin.
Next Document: The distribution and elimination of methotrexate in mouse blood and brain after concurrent administr...